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Cardiovascular (CV) disease, including coronary artery disease 
(CAD) is the leading cause of death in adults with type 2 diabe-
tes [1], because accompanied other risk factors such as dyslipi-
demia, hypertension, prothrombic and proinflammatory fac-
tors each contribute to accelerated atherosclerosis in obese type 
2 diabetes mellitus [2]. Still, the pathophysiologic mechanisms 
accounting for a substantially increased risk for CAD in adult 
type 2 diabetes remain unclear. A great efforts for discovery 
and validation of the novel risk factors in order to potentially 
identify high-risk individuals that may benefit from aggressive 
preventive strategies have been performed nowadays.
  It has been extensively demonstrated that inflammation 
plays a pivotal role in atherosclerosis, and that inflammatory 
markers such as C-reactive protein (CRP), fibrinogen, metallic 
metalloproteinase-9 (MMP-9), lipoprotein-associated phos-
pholipase A2 (Lp-PLA2), interleukin-6 (IL-6), tumor necrosis 
factor α (TNF-α) and beta-fibroblast growth factor (bFGF), 
may aid in the detection of individuals at higher CV risk [3-5]. 
In almost all the studies, the association between inflammato-
ry markers and coronary atherosclerosis was weak and mostly 
explained by concomitant burden of CAD risk factors. Al-
though measurements of these inflammatory markers have 
been immense promise as predictive markers for future CAD, 
currently there is lack of strong evidence that it adds signifi-
cantly to global risk assessment [6].
  Various adipocytokines, such as leptin, adiponectin, resistin, 
and retinol-binding protein 4 (RBP-4) have been reported to as-
sociate the obesity, insulin resistance, and finally CV events [7-
10]. Circulating levels of these cytokines can be used as high-
throughput biomarkers to assess the obesity-related health prob-
lems, including low grade inflammation.
  Cystatin C is a novel endogenous marker of kidney function 
that may be more sensitive for detecting mild to moderate dec-
rements in glomerular filtration rate [11]. Cystatin C is superi-
or to serum creatinine or creatinine-based estimating equa-
tions for prediction of all-cause mortality, CV events, and inci-
dent congestive heart failure in elderly community-based co-
horts [12-15]. The Framingham Offspring prospective cohort 
study showed the independent association with CV risk factors 
such as age, female sex, BMI, low high density lipoprotein cho-
lesterol (HDL-C), and smoking in 3,241 participants [14]. 
Third National Health and Nutrition Examination Survey par-
ticipants were subvidived according to cystatin C quartiles, and 
the prevalence of CVD myocardial infarction, agina pectoris, 
and stroke increased with increasing concentrations of cystatin 
C, and after adjustment for age, sex, race, and principal CV risk 
factors, cystatin C was independently associated with CVD 
[15]. Concomitant chronic kidney disease predicts CV events 
as strongly as other established risk factors [16], and low uri-
nary creatinine excretion rate has been suggested as a modifi-
able risk factor for mortality among persons with CAD [17]. 
However, 10 year follow-up study in a community-based pop-
ulation of elderly subjects found no evidence that cystatin C 
was a better risk prediction than creatinine or creatinine clear-
ance, suggesting further investigation should be required [18]. 
  Kim et al. [19] reported in this issue that there was no asso-
ciation between serum cystatin C level and CAD in diabetic 
patients. They found the serum cystatin C levels was signifi-
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cantly higher in patients with diabetic nephropathy, both in 
CAD patients and non-CAD patients.
  Recent studies have been suggesting complementary prog-
nostic value of multiple biomarkers approach to improve pre-
diction of CV risk. Approach with multiple inflammatory 
markers might be of interest since different inflammatory 
markers may enhance or initiate different and not always over-
lapping inflammatory pathways leading to atherosclerosis and 
cardiac events and lay indicate different stage of atherosclerosis.
  Several non-invasive markers of subclinical such as flow-
mediated dilatation in the brachial artery, carotid intima-me-
dial thickness, and pulse wave velocity have been associated 
with significant, but not always strong relationships with both 
traditional risk factors of CVD and inflammatory markers. 
  In conclusion, it is possible that a multimarker approach us-
ing a combination of these non-invasive test as well as various 
biomarkers including serum cystiatin C would also be useful 
in clinical practice, since each test is related only weakly with 
each other, and reflect different aspects of the atherosclerotic 
process. 
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